South Jordan, Utah (PRWEB UK) 14 November 2013
SOUTH JORDAN, UTAH— Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable medical devices used in interventional and diagnostic procedures, particularly in cardiology, radiology and endoscopy, today announced that Merit engineers will offer solutions to engineering questions at the 2013 Compamed Trade Fair taking place at the Düsseldorf Fairgrounds in Düsseldorf, Germany from November 20-22.
Merit Medical’s Engineering Manager David Keane, based at Merit’s Hypotube Center of Excellence in Galway, Ireland, will present “A discussion about hypotube laser technology.” The 10-minute presentation will be followed by a Question and Answer session and will offer information about laser technology and how it’s used in hypotube manufacturing. The discussion will be held at the Merit Medical Booth 8AL28 on Wednesday and Thursday, November 20 and 21, at 11:00 a.m.
Merit Medical’s Director of OEM Product Engineering, Dave Johnson, based in Salt Lake City, will present “Catheter Urethane Marker Bands.” The 10-minute presentation will offer information to help guide decisions about the use of urethane marker bands for catheters. The discussion will be held at the Merit Medical Booth 8AL28 on Wednesday and Thursday, November 20 and 21, at 2:00 p.m.
A professional barista will serve fresh coffee and espresso at the booth for attendees of the Customer Solution presentations. Following both sessions, Merit Medical staff will be available to discuss manufacturing capabilities available at Merit’s new hypotube Center of Excellence and its catheter marker band expertise.
More than 600 exhibitors from 39 countries and more than 16,000 visitors will attend Compamed 2013, an international trade show for the medical supplier industry. Compamed takes place in connection with Medica, the world‘s largest medical marketplace. (http://www.compamed-tradefair.com/)
ABOUT MERIT MEDICAL SYSTEMS, Inc.
Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture and distribution of proprietary disposable medical devices used in interventional and diagnostic procedures, particularly in cardiology, radiology and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force totaling approximately 200 individuals. Merit employs approximately 3,000 people worldwide with facilities in South Jordan, Utah; Angleton, Texas; Richmond, Virginia; Malvern, Pennsylvania; Maastricht and Venlo, The Netherlands; Paris, France; Galway, Ireland; Beijing, China; Copenhagen, Denmark; and Rockland, Massachusetts.
Merit Medical OEM (http://www.meritoem.com), a division of Merit Medical Systems, supplies medical device components and innovative devices to OEM customers around the world. Merit OEM has partnered with some of the world’s largest and most successful medical device companies on products including stock components and private labeled devices, to custom kits and trays and provides customization capabilities as well as engineering and design support. Merit Medical Coatings (http://www.meritmedicalcoatings.com) manufactures medical device components including hypotube/catheter shafts, guide wire components, needles and mandrels, and works with customers on custom solutions from the design phase through finishing details including coiling, laser cutting and ablation. Merit Medical Coatings is a world leader in the application of PFOA-free, PTFE and hydrophilic coating options for bulk quantities of medical wires and tubes.
Statements contained in this release which are not purely historical, including, without limitation, statements regarding Merit's forecasted revenues, net income, financial results or anticipated acquisitions, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties such as those described in Merit's Annual Report on Form 10-K for the year ended December 31, 2012. Such risks and uncertainties include risks relating to Merit's potential inability to successfully manage growth through acquisitions, including the inability to commercialize technology acquired through completed, proposed or future transactions; product recalls and product liability claims; expenditures relating to research, development, testing and regulatory approval or clearance of Merit's products and risks that such products may not be developed successfully or approved for commercial use; greater governmental scrutiny and regulation of the medical device industry; reforms to the 510(k) process administered by the U.S. Food and Drug Administration; compliance with governmental regulations and administrative procedures; potential restrictions on Merit's liquidity or its ability to operate its business in compliance with its current debt agreements and the consequences of failing to comply with such agreements; possible infringement of Merit's technology or the assertion that Merit's technology infringes the rights of other parties; the potential of fines, penalties, or other adverse consequences if Merit's employees or agents violate the U.S. Foreign Corrupt Practices Act or other laws and regulations; laws targeting fraud and abuse in the healthcare industry; potential for significant adverse changes in, or failure to comply with, governing regulations; the effect of changes in tax laws and regulations in the United States or other countries; the administrative burden and the expense associated with the Medical Device Excise Tax; increases in the price of commodity components; negative changes in economic and industry conditions in the United States and other countries; termination or interruption of relationships with Merit's suppliers, or failure of such suppliers to perform; fluctuations in Euro and GBP exchange rates; Merit's need to generate sufficient cash flow to fund its debt obligations, capital expenditures, and ongoing operations; concentration of Merit's revenues among a few products and procedures; development of new products and technology that could render Merit's existing products obsolete; market acceptance of new products; volatility in the market price of Merit's common stock; modification or limitation of governmental or private insurance reimbursement policies; changes in health care markets related to health care reform initiatives; failure to comply with applicable environmental laws; changes in key personnel; work stoppage or transportation risks; uncertainties associated with potential healthcare policy changes which may have a material adverse effect on Merit; introduction of products in a timely fashion; price and product competition; availability of labor and materials; cost increases; fluctuations in and obsolescence of inventory; and other factors referred to in Merit's Annual Report on Form 10-K for the year ended December 31, 2012 and other materials filed with the Securities and Exchange Commission. All subsequent forward-looking statements attributable to Merit or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Actual results will differ, and may differ materially, from anticipated results. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results, and Merit assumes no obligation to update or disclose revisions to those estimates.